One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Development and Validation of Data-Driven Estimates of Recurrence Risk and Treatment Benefit in Early Breast Cancer.
doi : 10.1200/JCO-24-02452
Volume 43(8) pgs. 899-1046 March 10, 2025
Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.
doi : 10.1200/JCO-24-01802
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
doi : 10.1200/JCO.24.00921
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
doi : 10.1200/JCO-24-01507
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.
doi : 10.1200/JCO.24.00237
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
doi : 10.1200/JCO.24.00400
Randomized Controlled Trial of a Virtually Delivered Exercise and Stress Management Program to Improve Physical Performance of Hematopoietic Cell Transplant Survivors.
doi : 10.1200/JCO.24.00333
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET).
doi : 10.1200/JCO.23.02724
Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.
doi : 10.1200/JCO-24-01715
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
doi : 10.1200/JCO-24-01278
Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.
doi : 10.1200/JCO-24-02081
Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?.
doi : 10.1200/JCO-24-02080
Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer?.
doi : 10.1200/JCO-24-02435
Erratum: Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
doi : 10.1200/JCO-24-01646
Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
doi : 10.1200/JCO-25-00116
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors.
doi : 10.1200/JCO-25-00252
